Sarpogrelate SR + Sarpogrelate

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Arterial Occlusive Diseases

Conditions

Arterial Occlusive Diseases, Intermittent Claudication

Trial Timeline

Nov 18, 2020 → Mar 9, 2023

NCT ID

NCT06046196

About Sarpogrelate SR + Sarpogrelate

Sarpogrelate SR + Sarpogrelate is a approved stage product being developed by Yuhan for Arterial Occlusive Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT06046196. Target conditions include Arterial Occlusive Diseases, Intermittent Claudication.

What happened to similar drugs?

20 of 20 similar drugs in Arterial Occlusive Diseases were approved

Approved (20) Terminated (7) Active (0)

✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved

✅RiociguatMerckApproved

✅SotaterceptMerckApproved

✅Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.AmgenApproved

✅Ambrisentan + Placebo + Sildenafil + TadalafilGilead SciencesApproved

✅AmbrisentanGilead SciencesApproved

✅Ambrisentan plus Spironolactone + Ambrisentan plus PlaceboGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06046196	Approved	Completed	Nov 18, 2020	Mar 9, 2023	Arterial Occlusive Diseases

Competing Products

20 competing products in Arterial Occlusive Diseases

See all competitors

Product	Company	Stage	Hype Score
CS1 Administration	Cereno Scientific	Phase 2	29
CS1	Cereno Scientific	Pre-clinical	24
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	25
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	39
edoxaban + Clopidogrel + Aspirin	Daiichi Sankyo	Phase 2	35
tadalafil and ambrisentan upfront combination therapy	Eli Lilly	Approved	43
Tadalafil- Tablet or Oral suspension	Eli Lilly	Phase 1/2	32
tadalafil	Eli Lilly	Pre-clinical	26
Orforglipron + Placebo	Eli Lilly	Phase 3	47
NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo	Nippon Shinyaku	Phase 2	42
Olaparib	AstraZeneca	Phase 1/2	24
SCH 530348	Merck	Phase 2	35
MK-8892 + Placebo for MK-8892	Merck	Phase 1	29
Riociguat	Merck	Approved	35
Sotatercept	Merck	Approved	50
Sotatercept + Background PAH Therapy	Merck	Phase 2	35
Sotatercept + Placebo + Background PAH Therapy	Merck	Phase 3	40
Sotatercept	Merck	Phase 3	40
Sotatercept	Merck	Phase 3	40
Frespaciguat + Placebo	Merck	Phase 1	29